In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.59 below Allarity Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 382 other companies have achieved higher Quick Ratio than Allarity Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 2003 to 2283.

Explain Quick Ratio?
How much Cash & cash equivalents ALLR�s has?
What are ALLR�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ALLR Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	216.21 %	153.17 %	-35.14 %	18.49 %	-14.86 %
Y / Y Cash & cash equivalent Change	-4.6 %	-21.38 %	-24.81 %	-8.49 %	-7.45 %
Quick Ratio MRQ	0.59	0.71	2.09	1.92	1.97
ALLR's Total Ranking	# 2283	# 2003	# 1287	# 1056	# 970
Seq. Current Liabilities Change	2.06 %	298.34 %	-19.98 %	-2.8 %	-18.29 %
Seq. Cash & cash equivalent Change	-14.28 %	34.89 %	-13.07 %	-5.09 %	-29.36 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 383
Healthcare Sector	# 712
Overall Market	# 2283

Quick Ratio Statistics
High	Average	Low
2.49	0.87	0.01
(Sep 30 2024)		(Jun 30 2019)

Financial Statements
Allarity Therapeutics Inc 's Current Liabilities	$ 29 Millions	Visit ALLR's Balance sheet
Allarity Therapeutics Inc 's Cash & cash equivalent	$ 17 Millions	Visit ALLR's Balance sheet
Source of ALLR's Sales		Visit ALLR's Sales by Geography

Cumulative Allarity Therapeutics Inc 's Quick Ratio

ALLR's Quick Ratio for the trailling 12 Months

ALLR Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	88.77 %	32.37 %	-23.39 %	2.39 %	-18.61 %
Y / Y Cash & cash equivalent TTM Growth	-15.58 %	-16.06 %	29.62 %	89.64 %	226.34 %
Quick Ratio TTM	0.94	1.31	2.08	2	2.11
Total Ranking TTM	# 4004	# 3095	# 3011	# 2845	# 2935
Seq. Current Liabilities TTM Growth	36.97 %	47.17 %	-9.59 %	3.57 %	-3.95 %
Seq. Cash & cash equivalent TTM Growth	-1.18 %	-7.23 %	-6.1 %	-1.94 %	-1.74 %

Quick ratio ranking by company, industry and sector >> Back to ALLR Financial Strength Comparisons >> Go to Compare ALLR Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2026 to $28.58 millions, cumulative Quick Ratio decreased to 0.94 above the ALLR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 436 other companies have achieved higher Quick Ratio than Allarity Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3095 to 4004.

Explain Quick Ratio?
How much Cash & cash equivalents ALLR�s has?
What are ALLR�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 437
Healthcare Sector	# 897
Within the Market	# 4004

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.11	0.84	0
(Jun 30 2025)		(Sep 30 2019)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Quoin Pharmaceuticals Ltd	1.63	$ 10.800 Millions	$ 6.613 Millions
Mallinckrodt Plc	1.63	$ 1,075.800 Millions	$ 660.600 Millions
Macrogenics Inc	1.59	$ 173.305 Millions	$ 108.815 Millions
Fibrobiologics Inc	1.59	$ 3.515 Millions	$ 2.213 Millions
Sarepta Therapeutics Inc	1.57	$ 788.489 Millions	$ 502.908 Millions
Revium Rx.	1.55	$ 1.506 Millions	$ 0.971 Millions
Liquidia Corporation	1.50	$ 284.181 Millions	$ 189.298 Millions
Greenwich Lifesciences Inc	1.50	$ 8.876 Millions	$ 5.923 Millions
Arcutis Biotherapeutics Inc	1.49	$ 238.552 Millions	$ 160.340 Millions
Mirum Pharmaceuticals Inc	1.48	$ 330.728 Millions	$ 222.788 Millions
Regeneron Pharmaceuticals Inc	1.45	$ 7,994.600 Millions	$ 5,530.600 Millions
Imunon Inc	1.44	$ 6.900 Millions	$ 4.779 Millions
Zai Lab Limited	1.44	$ 617.522 Millions	$ 428.584 Millions
Mannkind Corporation	1.44	$ 205.271 Millions	$ 142.898 Millions
Kyntra Bio Inc	1.41	$ 50.644 Millions	$ 36.040 Millions
Medicus Pharma Ltd	1.40	$ 15.174 Millions	$ 10.841 Millions
Aurinia Pharmaceuticals Inc	1.39	$ 179.732 Millions	$ 129.084 Millions
Omeros Corporation	1.39	$ 131.953 Millions	$ 94.963 Millions
Avenue Therapeutics Inc	1.38	$ 1.942 Millions	$ 1.407 Millions
Royalty Pharma Plc	1.33	$ 836.986 Millions	$ 630.928 Millions
Cormedix Inc	1.31	$ 256.692 Millions	$ 196.535 Millions
Transcode Therapeutics Inc	1.30	$ 8.383 Millions	$ 6.430 Millions
Elite Pharmaceuticals Inc	1.28	$ 39.032 Millions	$ 30.442 Millions
Ani Pharmaceuticals Inc	1.27	$ 360.212 Millions	$ 283.655 Millions
Pmgc Holdings Inc	1.25	$ 19.126 Millions	$ 15.329 Millions
Petros Pharmaceuticals inc	1.23	$ 3.489 Millions	$ 2.845 Millions
Nature s Sunshine Products inc	1.20	$ 82.503 Millions	$ 68.745 Millions
Phathom Pharmaceuticals Inc	1.19	$ 182.478 Millions	$ 153.777 Millions
Compass Pathways Plc	1.18	$ 433.720 Millions	$ 367.285 Millions
Geovax Labs Inc	1.17	$ 3.163 Millions	$ 2.712 Millions

Date modified: 2026-09-12T06:26:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.